COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Eradication of Prostate Cancer Using F-989

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01987999
Recruitment Status : Completed
First Posted : November 20, 2013
Last Update Posted : September 20, 2019
Information provided by (Responsible Party):
Optimal Health Research

Brief Summary:
The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Condition or disease Intervention/treatment Phase
Prostate Cancer Dietary Supplement: Acetogenins Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Eradication of Prostate Cancer Using F-989
Study Start Date : February 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Acetogenins
Acetogenins twice (BID) per day for 12 months
Dietary Supplement: Acetogenins

Primary Outcome Measures :
  1. Gleason Score [ Time Frame: 1 year ]
    A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary Outcome Measures :
  1. Prostate Specific Antigens (PSA) [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of prostate cancer
  • Referred to the study by their treating physician

Exclusion Criteria:

- Any type of treatment before starting study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01987999

Sponsors and Collaborators
Optimal Health Research
Layout table for investigator information
Principal Investigator: Steven Osguthorpe, ND Optimal Health Research
Layout table for additonal information
Responsible Party: Optimal Health Research Identifier: NCT01987999    
Other Study ID Numbers: F-9892131
First Posted: November 20, 2013    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases